Masimo (NASDAQ:MASI) Releases Q3 Earnings Guidance

Masimo (NASDAQ:MASI) issued an update on its third quarter earnings guidance on Wednesday morning. The company provided earnings per share (EPS) guidance of $0.81-0.86 for the period, compared to the consensus estimate of $0.84. The company issued revenue guidance of $495-515 million, compared to the consensus revenue estimate of $502.48 million.

Masimo Stock Performance

Shares of NASDAQ MASI opened at $126.18 on Wednesday. The stock has a fifty day moving average price of $115.66 and a two-hundred day moving average price of $124.85. The company has a debt-to-equity ratio of 0.55, a quick ratio of 1.15 and a current ratio of 2.09. The firm has a market cap of $6.71 billion, a P/E ratio of 85.84 and a beta of 0.98. Masimo has a 1 year low of $75.22 and a 1 year high of $153.93.

Masimo (NASDAQ:MASI) last issued its quarterly earnings results on Tuesday, August 6th. The medical equipment provider reported $0.86 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.77 by $0.09. The firm had revenue of $496.30 million during the quarter, compared to analyst estimates of $493.92 million. Masimo had a return on equity of 14.07% and a net margin of 3.94%. The firm’s quarterly revenue was up 9.0% on a year-over-year basis. During the same period last year, the company posted $0.62 EPS. Research analysts forecast that Masimo will post 3.87 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities analysts recently weighed in on MASI shares. Piper Sandler lifted their price target on Masimo from $160.00 to $165.00 and gave the stock an overweight rating in a research note on Wednesday, August 7th. Needham & Company LLC reiterated a hold rating on shares of Masimo in a report on Friday, September 20th. Four research analysts have rated the stock with a hold rating and four have given a buy rating to the stock. According to MarketBeat, the stock presently has an average rating of Moderate Buy and a consensus price target of $144.67.

Masimo Company Profile

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.